Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics

In developing traditional monoclonal antibodies (mAbs), drug manufacturers have often postponed addressing glycosylation issues until downstream processing.

The new generation of antibody therapeutics, however, offers no such leeway.

Compared with conventional mAbs, newer antibody therapeutics such as bispecific antibodies (BsAbs), antibody-drug conjugates (ADCs), Fc-fusion proteins, and advanced immunotherapies are far more sensitive to glycan heterogeneity. Even subtle variations in glycosylation can directly influence therapeutic efficacy and batch-to-batch consistency.

For these newer therapeutics, glycosylation must therefore be considered from the earliest stages of cell line and process development.

This priority shift is redefining expectations for contract development and manufacturing organizations (CDMOs). This article explains how CDMOs can efficiently move their glycosylation processes upstream using quality-by-design (QbD) methodologies.

Early glycosylation control drivers

The growing emphasis on upstream glycosylation control is primarily a consequence of increasing biologic complexity. Traditional mAbs are significantly more predictable in behavior, typically displaying stable glycosylation profiles in later clinical phases that pose minimal threat to efficacy or safety.

Modern biologics present a markedly different challenge:

• BsAbs rely upon highly precise structural configurations to facilitate simultaneous engagement of multiple targets. As a result, even relatively minor glycan asymmetry may impair target binding or compromise functional activity.
• ADCs introduce further complexity, with glycosylation influencing drug-antibody ratio (DAR) stability, payload retention, and overall molecular integrity.
• Fc-fusion proteins and immunotherapies frequently depend upon tightly controlled glycan profiles to achieve appropriate pharmacokinetic behavior and immune system engagement.

Historically, downstream processing provided manufacturers with opportunities to compensate for variability introduced upstream. Adjustments during purification or process optimization frequently proved sufficient to address modest glycosylation inconsistencies associated with conventional antibody therapeutics.

However, this approach is increasingly inadequate for modern biologics. In certain cases, even a minor shift in specific glycan variants can critically compromise the drug’s pharmacokinetic profile, therapeutic efficacy, or safety. Many of these glycosylation-related challenges originate at the cellular and metabolic level during biosynthesis. Once heterogeneous glycan populations have been established, downstream interventions are inherently limited in their ability to fully correct structural inconsistencies.

Consequently, the industry is transitioning away from reactive correction models toward proactive upstream quality engineering.

Mitigating regulatory and commercial risk

Integrating quality considerations earlier in development offers significant regulatory and commercial advantages. If glycosylation inconsistencies emerge during scale-up or commercial manufacturing, the consequences may include batch rejection, additional comparability studies, regulatory delays, or disruptions to clinical programs.

Regulatory frameworks, including ICH Q8, Q9, and Q11, require manufacturers to identify critical quality attributes (CQAs), understand sources of process variability, and establish scientifically justified control strategies. For biologics, glycosylation has long been recognized as an important quality attribute linked to safety, efficacy, and immunogenicity. However, the increasing complexity of newer modalities has intensified expectations around early process understanding and glycan control.

Consequently, proactive upstream glycosylation control helps manufacturers meet these expectations by improving process consistency throughout development and scale-up. It also strengthens regulatory submissions by demonstrating that glycan heterogeneity is understood, monitored, and appropriately controlled across the manufacturing process.

Clone selection is critical to consistency

When implementing proactive control of glycosylation upstream, manufacturers must recognize that glycan variability is highly clone-dependent.

A substantial proportion of glycosylation variability, around 80%, originates from the intrinsic characteristics of the production clone itself. Even minor differences in genes such as MGAT1 and FUT8 in a clone can alter the clone’s Golgi enzyme expression, which in turn can affect the branching/ fucosylation of subsequent antibodies, thereby affecting antibody-dependent cellular cytotoxicity (ADCC). A single glycan variant can therefore destroy a therapeutic’s mechanism of action.

Consider an Fc-fusion immunotherapy targeting the interleukin-6 receptor. If produced from a clone with high mannose levels, the eventual therapeutic’s half-life could drop from an expected 21 days to three days. Failure to eliminate unsuitable clones during early development may therefore result in otherwise promising candidates exhibiting unacceptable clinical characteristics during later stages.

For this reason, developers must increasingly assess glycan quality attributes in addition to productivity and titer in early screening activities as part of their clone selection strategies.

Glycosylation-related quality attributes should be assessed in the context of the molecule’s intended mechanism of action and functional requirements. Examples include:

• Fucosylation levels: As an influencing factor in ADCC activity, fucosylation levels are particularly important for oncology therapeutics and immune-engaging molecules.
• Galactosylation patterns: These patterns are significant where complement-dependent cytotoxicity (CDC) activity is required, as increased galactosylation may enhance C1q binding.
• Sialic acid linkage profiles: Different sialylation patterns may influence inflammatory responses and pharmacokinetic performance in distinct ways, requiring careful evaluation. Also, sialic acids have a direct, strong correlation with the charge variant profiles, especially with the acidic variants, which can affect the binding affinity, immunogenicity, and other critical attributes.

• High mannose content: As high mannose content can influence clearance rates and immunogenicity risk, it is an increasingly important quality consideration.

High-throughput analytics are transforming cell line development

To evaluate glycosylation-related attributes effectively during early-stage development, drug developers and CDMOs are increasingly utilizing advanced analytical technologies, including HILIC-UPLC, LC-MS glycopeptide mapping, HPLC, and capillary electrophoresis. By integrating these high-throughput methodologies directly into early screening workflows, these organizations can simultaneously assess productivity and glycan quality, thereby reducing the likelihood that unsuitable clones progress through development.

Importantly, the objective is not necessarily to identify clones exhibiting a perfect glycan profile but rather to identify clones that naturally align as closely as possible with the target profile from the outset, thereby minimizing the extent of subsequent optimization required.

Structured experimental design

As biologic systems become increasingly complex, intuition-based optimization approaches are becoming insufficient.

Numerous upstream variables, including temperature, pH, substrate composition, oxygen transfer, amino acid availability, and lipid concentrations, may influence glycosylation pathways within the Golgi apparatus. Even relatively minor variations in culture conditions may alter branching patterns, fucosylation levels, or sialylation outcomes.

Managing this complexity requires structured and statistically robust methodologies.

Design of experiments (DoE) approaches are therefore becoming essential for identifying critical process parameters while minimizing experimental burden. Screening DoEs allow developers to evaluate which parameters most significantly affect glycosylation outcomes, while optimization DoEs facilitate refinement of process conditions to balance productivity with quality objectives.

These methodologies also support broader QbD principles increasingly emphasized by regulators, including the establishment of process design spaces and robust monitoring strategies under frameworks such as ICH Q8 and Q11.

The role of automation, analytics, and data integration 

Looking ahead, the continued evolution of upstream glycosylation control is likely to be driven by advances in automation and data analytics.

Many organizations have already begun integrating online monitoring technologies and automated feedback systems into bioprocessing workflows. Over time, these systems are expected to become increasingly sophisticated, enabling more dynamic adjustment of bioreactor conditions in response to real-time glycan analytics.

Artificial intelligence (AI) and machine learning are also expected to play increasingly important roles. As larger multi-batch datasets become available, AI-driven models may help predict relationships between process parameters and glycosylation outcomes with greater speed and accuracy than traditional analytical approaches alone.

However, realizing these capabilities will require substantial investment in organizational infrastructure.

Glycosylation in the years to come

No longer a downstream consideration, glycosylation control is set to play an increasingly important role in biologics development and manufacturing strategies.

For biopharma companies and CDMOs, this change will require stronger, AI-enabled technical capabilities to integrate volumes of analytical and manufacturing data effectively at speed, so operators can better understand how upstream conditions may influence glycan outcomes throughout scale-up and commercial production.

Timely insights such as these will only become more vital as the range of biologic modalities continues to diversify and as regulatory expectations surrounding consistency continue to evolve.

Going forward, organizations that integrate these considerations from the outset will be better positioned to support consistent therapeutic performance, reduce late-stage risk, and meet the growing demands associated with next-generation biologics.

Sojeong Lee, PhD, is director of upstream development at Samsung Biologics

The post Why Glycosylation Control Is No Longer a Secondary Concern in the Development of Complex Biologics appeared first on GEN - Genetic Engineering and Biotechnology News.